We are monitoring the impact of COVID-19 on APAC Oncology Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date September, 2021
ID: 12199
Share on
Share on

APAC Oncology Drugs Market Research Report – Segmented By type, drug class, distribution channel, route of administration, drug classification, & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast | 2021 to 2026

Pulished: September, 2021
ID: 12199
Pages: 100

APAC Oncology Drugs Market Size (2021 to 2026)

The APAC Oncology Drugs Market was worth USD 38.30  billion in 2021 and is estimated to be growing at a CAGR of 11.01%, to reach USD 64.57 billion by 2026.

Oncology helps study, diagnosis, and treatment of cancer. Cancer is a disease where abnormal cells grow uncontrollably and disrupt normal bodily functions.

The demand for cancer medicines grows in tandem with the number of cancer diagnoses and fatalities. As a result, this factor has a significant bearing on the oncology market. Furthermore, there has been a greater emphasis on medical research in order to reduce cancer cases. The market is also expanding as healthcare costs rise in different parts of the world. Globally, 9.6 million people died of cancer in 2018, according to the World Health Organization. Increased cancer incidences have boosted the oncology market, propelling the cancer therapy sector forward. Targeted Therapy has grown in prominence as a cancer treatment throughout time. They have several advantages over traditional treatment techniques like chemotherapy, radiation, and others. It can be used alone or in combination with other therapies such as radiotherapy or chemotherapy. They are effective because they have no effect on the cells in their immediate vicinity. These cutting-edge cancer treatment technologies and methods, together with rising healthcare spending in developing countries, are likely to propel the APAC oncology drugs market.

However, Chemotherapy medications destroy cancer cells and harm healthy cells in the body, resulting in various adverse effects for the patient. Bone marrow suppression, gastrointestinal disorders, neuropathies, hair loss, weariness, and skin diseases are the most prevalent side effects. As a result, the market's expansion is hampered by the bad effects of oncology medications. Other factors that are limiting the global market expansion throughout the projection period include tight government regulations, high medical costs, and patient expiration.

The extensive product portfolios and pipeline medicines, CELGENE, Novartis, and Roche, have been established as major participants in the Asia Pacific oncology medications industry, capturing a significant market share. Roche's oncology medications and therapies have seen rapid uptakes, such as Avastin, Herceptin, and Rituxan. Companies in the generic cancer pharmaceuticals sector have created strategic agreements to help them focus their efforts on creating high-efficacy generic oncology treatments. These strategic moves have paid off handsomely for these companies, allowing them to maintain their generic cancer medicine market dominance.

In most developed countries, health technology evaluation is becoming more common. Price control is a significant concern in the oncology medicine industry, and financial risk-sharing agreements are frequently used. Disparities in pricing between original brands and generics are being investigated. To improve the local relevance of trials in Asian nations' regulatory processes and minimize time to market, global trials are boosting the recruitment of Asian patients. Manufacturers should guarantee that product development initiatives are aligned internally from the start.

This research report on the APAC oncology drugs market has been segmented and sub-segmented into the following categories:

By Type:

  • Lung Cancer
  • Pancreatic Cancer
  • Breast Cancer
  • Prostate Cancer
  • Ovarian Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Kidney Cancer
  • Brain Cancer
  • Thyroid Cancer
  • Skin Cancer
  • Bladder Cancer
  • Cervical Cancer
  • Blood Cancer
  • Others

By Drug Class Type:

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies/Drug Stores
  • Others

By Route of Administration:

  • Oral
  • Parenteral
  • Others

By Drug Classification:

  • Branded Drugs
  • Generic Drugs

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand, Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

The APAC is one of the fastest-growing regions globally in the oncology drugs market. For common cancer medicine therapy, the Asia Pacific area follows most of the global patterns. Lung cancer is the most prevalent sort of drug use in Asia, while prostate cancer is the most common in the West. Breast cancer is also the most frequent type of cancer in Asian women. Cervical and liver cancers, on the other hand, are more common in other areas. In the procurement of various anticancer prescription treatments, Asia Pacific plays a vital role. In terms of cancer oncology drugs, Asia Pacific has the biggest market share. 

Some nations, such as China, India, and Japan, play a significant role in the cancer oncology market. In addition, the government established a healthcare budget, and several multi-national organizations are funding cancer medications. As a result, better cancer pharmaceutical treatments are being introduced to the market.

KEY MARKET PLAYERS:

F. Hoffmann-La Roche Ltd, Genentech, Inc., Novartis AG, Pfizer Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca, Sanofi, and Bayer AG are some of the notable companies in the APAC oncology drugs market.

1. Introduction                                   

            1.1 Market Definition            

            1.2 Scope of the report                     

            1.3 Study Assumptions                      

            1.4 Base Currency, Base Year and Forecast Periods             

2. Research Methodology                             

            2.1 Analysis Design                

            2.2 Research Phases              

                        2.2.1 Secondary Research     

                        2.2.2 Primary Research          

                        2.2.3 Data Modelling 

                        2.2.4 Expert Validation          

            2.3 Study Timeline                 

3. Report Overview                            

            3.1 Executive Summary                     

            3.2 Key Inferences                 

4. Market Dynamics                           

            4.1 Impact Analysis                

                        4.1.1 Drivers  

                        4.1.2 Restraints          

                        4.1.3 Opportunities   

            4.2 Regulatory Environment              

            4.3 Technology Timeline & Recent Trends                

5. Competitor Benchmarking Analysis                                  

            5.1 Key Player Benchmarking            

                        5.1.1 Market share analysis   

                        5.1.2 Products/Service          

                        5.1.3 Regional Presence        

            5.2 Mergers & Acquisition Landscape                       

            5.3 Joint Ventures & Collaborations              

6. Market Segmentation                                

            6.1 APAC Oncology drugs Market, By Type            

            6.2  Lung Cancer                    

            6.3   Pancreatic Cancer                      

            6.4 Breast Cancer                  

            6.5 Prostate Cancer               

            6.6 Ovarian Cancer                

            6.7    Colorectal Cancer                      

            6.8 Gastric Cancer                  

            6.9 Kidney Cancer                  

            6.10 Brain Cancer                  

            6.11 Brain Cancer                  

            6.12 Thyroid Cancer              

                        6.12.1 Market Size Estimations & Forecasts (2021-2026)    

                        6.12.2 Y-o-Y Growth Rate Analysis    

                        6.12.3 Market Attractiveness Index  

            6.13 APAC Oncology drugs Market, By Drug Class Type:                

            6.14 Chemotherapy               

            6.15  Targeted Therapy                     

            6.16   Immunotherapy (Biologic Therapy)                 

            6.17  Hormonal Therapy                    

                        6.17.1 Market Size Estimations & Forecasts (2021-2026)    

                        6.17.2 Y-o-Y Growth Rate Analysis    

                        6.17.3 Market Attractiveness Index  

            6.18 APAC Oncology drugs Market, By Distribution Channel:                     

            6.19 Hospital Pharmacies                  

            6.20  Retail Pharmacies/Drug Stores             

            6.21 Others                                                                

                        6.21.1 Market Size Estimations & Forecasts (2021-2026)    

                        6.21.2 Y-o-Y Growth Rate Analysis    

                        6.21.3 Market Attractiveness Index  

            6.22 APAC Oncology drugs Market, By Route of Administration:               

            6.23  Oral                   

            6.24 Parenteral                      

            6.25 Others                   

                        6.25.1 Market Size Estimations & Forecasts (2021-2026)    

                        6.25.2 Y-o-Y Growth Rate Analysis    

                        6.25.3 Market Attractiveness Index  

            6.26 APAC Oncology drugs Market, By Drug Classification:            

            6.27 Branded Drugs               

            6.28 Generic Drugs                       

                        6.28.1 Market Size Estimations & Forecasts (2021-2026)    

                        6.28.2 Y-o-Y Growth Rate Analysis    

                        6.28.3 Market Attractiveness Index  

7. Geographical Landscape                         

            7.1 Asia Pacific                       

                        7.1.1 By Country        

                                    7.1.1.1 China

                                    7.1.1.2 India

                                    7.1.1.3 Japan

                                    7.1.1.4 South Korea

                                    7.1.1.5 South East Asia

                                    7.1.1.6 Australia & NZ

                                    7.1.1.7 Rest of Asia-Pacific

                        7.1.2 By Type 

                        7.1.3  By Drug Class Type:     

                        7.1.4 By Distribution Channel:           

                        7.1.5 By Route of Administration:     

                        7.1.6 By Drug Classification:  

8. Key Player Analysis            

            8.1 Pfizer

8.1.1 Business Description    

                        8.1.2 Products/Service          

                        8.1.3 Financials          

                        8.1.4 SWOT Analysis  

                        8.1.5 Recent Developments  

8.1.6 Analyst Overview

            8.2 Johnson & Johnson

            8.3 Novartis

            8.4 Bristol-Meyers Squibb Company

            8.5 AstraZeneca PLC

            8.6 F Hoffmann-La Roche Ltd

            8.7 Merck & Co

            8.8 AbbVie Inc.

            8.9 Astellas Pharma Inc.

            8.10 Amgen Inc.

9. Market Outlook & Investment Opportunities                               

10. Appendix                           

            List of Tables              

            List of Figures       

  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and also identify the areas that are still untapped. 

  • The segment-level analysis in terms of type, drug class type, distribution channel, route of administration, drug classification, and region along with market size forecasts and estimations to detect key areas of industry growth in detail.

  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.

  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.

  • Study the microenvironment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development.

  • A comprehensive list of key market players along with their product portfolio, current strategic interests, essential financial information, legal issues, SWOT analysis, and analyst overview to study and sustain the market environment.

  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies, and recent developments in the market by the major companies

  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions.

  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations with a strong financial foothold in the market.

  1. Asia Pacific Global Oncology drugs Market, By Type, From 2021 to 2026 (USD Billion)

  2. Asia Pacific Lung Cancer Market, By Region, From 2021 to 2026 (USD Billion)

  3. Asia Pacific  Pancreatic Cancer Market, By Region, From 2021 to 2026 (USD Billion)

  4. Asia Pacific  Breast Cancer Market, By Region, From 2021 to 2026 (USD Billion)

  5. Asia Pacific   Prostate Cancer Market, By Region, From 2021 to 2026 (USD Billion)

  6. Asia Pacific Ovarian Cancer Market, By Region, From 2021 to 2026 (USD Billion)

  7. Asia Pacific   Colorectal Cancer Market, By Region, From 2021 to 2026 (USD Billion)

  8. Asia Pacific Gastric Cancer Market, By Region, From 2021 to 2026 (USD Billion)

  9. Asia Pacific Kidney Cancer Market, By Region, From 2021 to 2026 (USD Billion)

  10. Asia Pacific  Brain Cancer Market, By Region, From 2021 to 2026 (USD Billion)

  11. Asia Pacific   Thyroid Cancer Market, By Region, From 2021 to 2026 (USD Billion)

  12. Asia Pacific Global Oncology drugs Market, By Drug Class Type, From 2021 to 2026 (USD Billion)

  13. Asia Pacific Chemotherapy Market, By Region, From 2021 to 2026 (USD Billion)

  14. Asia Pacific  Targeted Therapy Market, By Region, From 2021 to 2026 (USD Billion)

  15. Asia Pacific  Immunotherapy (Biologic Therapy) Market, By Region, From 2021 to 2026 (USD Billion)

  16. Asia Pacific  Hormonal Therapy Market, By Region, From 2021 to 2026 (USD Billion)

  17. Asia Pacific Global Oncology drugs Market, By Distribution Channel, From 2021 to 2026 (USD Billion)

  18. Asia Pacific   Hospital Pharmacies Market, By Region, From 2021 to 2026 (USD Billion)

  19. Asia Pacific    Retail Pharmacies/Drug Stores Market, By Region, From 2021 to 2026 (USD Billion)

  20. Asia Pacific  Others Market, By Region, From 2021 to 2026 (USD Billion)

  21. Asia Pacific Global Oncology drugs Market, By Route of Administration, From 2021 to 2026 (USD Billion)

  22. Asia Pacific  Oral Market, By Region, From 2021 to 2026 (USD Billion)

  23. Asia Pacific Parenteral Market, By Region, From 2021 to 2026 (USD Billion)

  24. Asia Pacific Others Market, By Region, From 2021 to 2026 (USD Billion)

  25. Asia Pacific Global Oncology drugs Market, By Drug Classification, From 2021 to 2026 (USD Billion)

  26. Asia Pacific  Branded Drugs Market, By Region, From 2021 to 2026 (USD Billion)

  27. Asia Pacific   Generic Drugs Market, By Region, From 2021 to 2026 (USD Billion)

  28. Japan Global Oncology drugs Market, By Type, From 2021 to 2026 (USD Billion)

  29. Japan Global Oncology drugs Market, By Drug Class Type, From 2021 to 2026 (USD Billion)

  30. Japan Global Oncology drugs Market, By Distribution Channel, From 2021 to 2026 (USD Billion)

  31. Japan Global Oncology drugs Market, By Route of Administration, From 2021 to 2026 (USD Billion)

  32. Japan Global Oncology drugs Market, By Drug Classification, From 2021 to 2026 (USD Billion)

  33. China Global Oncology drugs Market, By Type, From 2021 to 2026 (USD Billion)

  34. China Global Oncology drugs Market, By Drug Class Type, From 2021 to 2026 (USD Billion)

  35. China Global Oncology drugs Market, By Distribution Channel, From 2021 to 2026 (USD Billion)

  36. China Global Oncology drugs Market, By Route of Administration, From 2021 to 2026 (USD Billion)

  37. China Global Oncology drugs Market, By Drug Classification, From 2021 to 2026 (USD Billion)

  38. India Global Oncology drugs Market, By Type, From 2021 to 2026 (USD Billion)

  39. India Global Oncology drugs Market, By Drug Class Type, From 2021 to 2026 (USD Billion)

  40. India Global Oncology drugs Market, By Distribution Channel, From 2021 to 2026 (USD Billion)

  41. India Global Oncology drugs Market, By Route of Administration, From 2021 to 2026 (USD Billion)

  42. India Global Oncology drugs Market, By Drug Classification, From 2021 to 2026 (USD Billion)

  43. Australia Global Oncology drugs Market, By Type, From 2021 to 2026 (USD Billion)

  44. Australia Global Oncology drugs Market, By Drug Class Type, From 2021 to 2026 (USD Billion)

  45. Australia Global Oncology drugs Market, By Distribution Channel, From 2021 to 2026 (USD Billion)

  46. Australia Global Oncology drugs Market, By Route of Administration, From 2021 to 2026 (USD Billion)

  47. Australia Global Oncology drugs Market, By Drug Classification, From 2021 to 2026 (USD Billion)

  48. South Korea Global Oncology drugs Market, By Type, From 2021 to 2026 (USD Billion)

  49. South Korea Global Oncology drugs Market, By Drug Class Type, From 2021 to 2026 (USD Billion)

  50. South Korea Global Oncology drugs Market, By Distribution Channel, From 2021 to 2026 (USD Billion)

  51. South Korea Global Oncology drugs Market, By Route of Administration, From 2021 to 2026 (USD Billion)

  52. South Korea Global Oncology drugs Market, By Drug Classification, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample